Efficacy and safety of FLOT combined with apatinib and sintilimab as a neoadjuvant therapy regimen for locally advanced gastric or gastroesophageal junction adenocarcinoma: An open-lable, single-arm, phase II study

被引：1
|
作者：
Zhou, H. [1 ]
Long, B. [2 ]
Yu, Z. [3 ]
Zhu, J. [2 ]
Yang, H. [4 ]
Zhang, W. [3 ]
Guan, X. [5 ]
Zhang, G. [2 ]
Li, L. [2 ]
Luo, C. [2 ]
Cao, H. [2 ]
Zhang, S. [2 ]
Chen, S. [2 ]
He, Q. [2 ]
Gan, S. [2 ]
Zhou, L. [2 ]
Jiang, X. [2 ]
Shi, W.
Huang, Z. [5 ]
Mao, J. [2 ]
Dong, C. [6 ]
Jiao, Z. [2 ]
机构：
[1] Gansu Prov Canc Hosp, Dept Abdominal Surg, Lanzhou, Peoples R China
[2] Lanzhou Univ Second Hosp, Dept Gen Surg, Lanzhou, Peoples R China
[3] Lanzhou Univ Second Hosp, Dept Radiol, Lanzhou, Peoples R China
[4] Lanzhou Univ Second Hosp, Cuiying Cent Lab, Lanzhou, Peoples R China
[5] Lanzhou Univ Second Hosp, Dept Gastroenterol, Lanzhou, Peoples R China
[6] Lanzhou Univ Second Hosp, Dept Pathol, Lanzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.202
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-146
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [31] Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
    Li, Jin
    Qin, Shukui
    Wen, Lu
    Wang, Junsheng
    Deng, Wenying
    Guo, Weijian
    Jia, Tongfu
    Jiang, Da
    Zhang, Guifang
    He, Yifu
    Ba, Yi
    Zhong, Haijun
    Wang, Lin
    Lin, Xiaoyan
    Yang, Jianwei
    Zhao, Jun
    Bai, Yuxian
    Wu, Xiangyuan
    Gao, Feng
    Sun, Guogui
    Wu, Yongjuan
    Ye, Feng
    Wang, Qiong
    Xie, Zhong
    Yi, Tienan
    Huang, Yong
    Yu, Guohua
    Lu, Lin
    Yuan, Ying
    Li, Wei
    Liu, Likun
    Sun, Yuping
    Sun, Ying
    Yin, Lifeng
    Hou, Zhiguo
    BMC MEDICINE, 2023, 21 (01)
  • [32] Surufatinib plus sintilimab in patients with advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, single-center phase II trial.
    Zhang, Dong-Sheng
    Liu, Fu-Rong
    Lu, Yun-Xin
    Bai, Bing
    Zhang, Yang
    Wang, Zhi-Qiang
    Liu, Yu
    Chen, Jian-Wen
    Wang, Feng
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 358 - 358
  • [33] Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy.
    Liu, Ning
    Liu, Zimin
    Zhou, Yanbing
    Niu, Zhaojian
    Jiang, Haitao
    Zhu, Yingqian
    Wang, Huiyun
    Li, Xiaoxiao
    Song, Shanai
    Liu, Xiaodong
    Li, Zequn
    Zhao, Shufen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Perioperative sintilimab combination with SOX for resectable locally advanced gastric/gastroesophageal junction cancer(GC/GEJC): Initial findings of a single-arm phase II trial
    Ding, Xuewei
    Li, Bin
    Xue, Qiang
    Cai, Mingzhi
    Cui, Jingli
    Wang, Baogui
    Ke, Bin
    Zhang, Rupeng
    Liang, Han
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [35] Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer: A prospective, single-arm, phase II clinical trial
    Zhang, P.
    Zhang, W.
    Liu, X.
    He, D.
    Yang, K.
    Gou, H.
    Hu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S903 - S903
  • [36] Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial
    Zheng, Yanan
    Yang, Xiao
    Yan, Chao
    Feng, Runhua
    Sah, Birendra Kumar
    Yang, Zhongyin
    Zhu, Zhenglun
    Liu, Wentao
    Xu, Wei
    Ni, Zhentian
    Beeharry, Maneesh Kumarsing
    Hua, Zichen
    Yan, Min
    Zhu, Zhenggang
    Li, Chen
    EUROPEAN JOURNAL OF CANCER, 2020, 130 : 12 - 19
  • [37] Conversion therapy of concurrent chemoradiotherapy combined with tislelizumab for unresectable gastric or gastroesophageal junction adenocarcinoma: A prospective, single-arm, phase II trial
    Liu, D.
    Yang, L.
    Lu, K.
    Zhao, Q.
    Yu, J.
    Liu, Y.
    Chen, Q.
    Liu, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S173 - S173
  • [38] Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma.
    Liu, Ying
    Han, Guangsen
    Li, Hongle
    Zhao, Yuzhou
    Zhuang, Jing
    Wang, Gangcheng
    Li, Baodong
    Wang, Jinbang
    Li, Zhimeng
    Xia, Qingxin
    Ma, Jie
    Zhang, Chengjuan
    Yu, Juan
    Li, Ke
    Xu, Shuning
    Qiao, Lei
    Kuang, Gaizhen
    Li, Danyang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma
    Shi, Jin-Ming
    Li, Ning
    Jiang, Li-Ming
    Yang, Lin
    Wang, Shu-Lian
    Song, Yong-Wen
    Liu, Yue-Ping
    Fang, Hui
    Lu, Ning-Ning
    Qi, Shu-Nan
    Chen, Bo
    Li, Ye-Xiong
    Zhao, Dong-Bing
    Tang, Yuan
    Jin, Jing
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [40] Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    Chao Jing
    Junyun Wang
    Mingyue Zhu
    Zhigang Bai
    Baoyi Zhao
    Jun Zhang
    Jie Yin
    Xiaobao Yang
    Zongzhi Liu
    Zhongtao Zhang
    Wei Deng
    Cancer Immunology, Immunotherapy, 2022, 71 : 2597 - 2608
12345